Your browser doesn't support javascript.
loading
Changes in renal function after nephroureterectomy for upper urinary tract carcinoma: analysis of a large multicenter cohort (Radical Nephroureterectomy Outcomes (RaNeO) Research Consortium).
Tafuri, Alessandro; Marchioni, Michele; Cerrato, Clara; Mari, Andrea; Tellini, Riccardo; Odorizzi, Katia; Veccia, Alessandro; Amparore, Daniele; Shakir, Aliasger; Carbonara, Umberto; Panunzio, Andrea; Trovato, Federica; Catellani, Michele; Janello, Letizia M I; Bianchi, Lorenzo; Novara, Giacomo; Dal Moro, Fabrizio; Schiavina, Riccardo; De Lorenzis, Elisa; Parma, Paolo; Cimino, Sebastiano; De Cobelli, Ottavio; Maiorino, Francesco; Bove, Pierluigi; Crocerossa, Fabio; Cantiello, Francesco; D'Andrea, David; Di Cosmo, Federica; Porpiglia, Francesco; Ditonno, Pasquale; Montanari, Emanuele; Soria, Francesco; Gontero, Paolo; Liguori, Giovanni; Trombetta, Carlo; Mantica, Guglielmo; Borghesi, Marco; Terrone, Carlo; Del Giudice, Francesco; Sciarra, Alessandro; Galosi, Andrea; Moschini, Marco; Shariat, Shahrokh F; Di Nicola, Marta; Minervini, Andrea; Ferro, Matteo; Cerruto, Maria Angela; Schips, Luigi; Pagliarulo, Vincenzo; Antonelli, Alessandro.
Afiliación
  • Tafuri A; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Piazzale Stefani 1, 37126, Verona, Italy. tafuri.alessandro@gmail.com.
  • Marchioni M; Department of Urology, "Vito Fazzi" Hospital, Lecce Piazza Filippo Muratore, 1, 73100, Lecce, Italy. tafuri.alessandro@gmail.com.
  • Cerrato C; Department of Neuroscience, Imaging and Clinical Sciences, G. D'Annunzio University, Chieti, Italy. tafuri.alessandro@gmail.com.
  • Mari A; Department of Urology, University of Chieti, Chieti, Italy.
  • Tellini R; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Piazzale Stefani 1, 37126, Verona, Italy.
  • Odorizzi K; Department of Urology, University of Florence, Florence, Italy.
  • Veccia A; Department of Urology, University of Florence, Florence, Italy.
  • Amparore D; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Piazzale Stefani 1, 37126, Verona, Italy.
  • Shakir A; Department of Urology, Mantua Hospital, Mantua, Italy.
  • Carbonara U; School of Medicine, Division of Urology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy.
  • Panunzio A; Keck School of Medicine, Institute of Urology, University of Southern California, Los Angeles, CA, USA.
  • Trovato F; Department of Urology, Aldo Moro University, Bari, Italy.
  • Catellani M; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Piazzale Stefani 1, 37126, Verona, Italy.
  • Janello LMI; Department of Surgery, Urology Section, University of Catania, Catania, Italy.
  • Bianchi L; Department of Urology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Novara G; Department of Urology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Dal Moro F; Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Schiavina R; Unit of Urology, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
  • De Lorenzis E; Unit of Urology, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
  • Parma P; Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Cimino S; Department of Urology, Foundation IRCCS Ca' Granda-Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
  • De Cobelli O; Department of Urology, Mantua Hospital, Mantua, Italy.
  • Maiorino F; Department of Surgery, Urology Section, University of Catania, Catania, Italy.
  • Bove P; Department of Urology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Crocerossa F; Urology Unit, San Carlo di Nancy Hospital - GVM Care and Research, Rome, Italy.
  • Cantiello F; Urology Unit, San Carlo di Nancy Hospital - GVM Care and Research, Rome, Italy.
  • D'Andrea D; Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy.
  • Di Cosmo F; Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy.
  • Porpiglia F; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Ditonno P; Department of Urology, "Vito Fazzi" Hospital, Lecce Piazza Filippo Muratore, 1, 73100, Lecce, Italy.
  • Montanari E; School of Medicine, Division of Urology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy.
  • Soria F; Department of Urology, Aldo Moro University, Bari, Italy.
  • Gontero P; Department of Urology, Foundation IRCCS Ca' Granda-Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
  • Liguori G; Division of Urology, Department of Surgical Sciences - Urology, Città della Salute e della Scienza di Torino - Molinette Hospital, University of Turin, Turin, Italy.
  • Trombetta C; Division of Urology, Department of Surgical Sciences - Urology, Città della Salute e della Scienza di Torino - Molinette Hospital, University of Turin, Turin, Italy.
  • Mantica G; Department of Urology, University of Trieste, Cattinara Hospital - ASUGI, Trieste, Italy.
  • Borghesi M; Department of Urology, University of Trieste, Cattinara Hospital - ASUGI, Trieste, Italy.
  • Terrone C; Department of Urology, Policlinico San Martino Hospital, University of Genova, Genoa, Italy.
  • Del Giudice F; Department of Urology, Policlinico San Martino Hospital, University of Genova, Genoa, Italy.
  • Sciarra A; Department of Urology, Policlinico San Martino Hospital, University of Genova, Genoa, Italy.
  • Galosi A; Department of Maternal-Infant and Urological Sciences, Sapienza/Policlinico Umberto I, Rome, Italy.
  • Moschini M; Department of Maternal-Infant and Urological Sciences, Sapienza/Policlinico Umberto I, Rome, Italy.
  • Shariat SF; Department of Urology, University of Ancona, Ancona, Italy.
  • Di Nicola M; Division of Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Minervini A; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Ferro M; Department of Medical, Oral and Biotechnological Sciences, G. d'Annunzio University of Chieti, Chieti, Italy.
  • Cerruto MA; Department of Urology, University of Florence, Florence, Italy.
  • Schips L; Department of Urology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Pagliarulo V; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Piazzale Stefani 1, 37126, Verona, Italy.
  • Antonelli A; Department of Urology, University of Chieti, Chieti, Italy.
World J Urol ; 40(11): 2771-2779, 2022 Nov.
Article en En | MEDLINE | ID: mdl-36203101
ABSTRACT

PURPOSE:

To investigate prevalence and predictors of renal function variation in a multicenter cohort treated with radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC).

METHODS:

Patients from 17 tertiary centers were included. Renal function variation was evaluated at postoperative day (POD)-1, 6 and 12 months. Timepoints differences were Δ1 = POD-1 eGFR - baseline eGFR; Δ2 = 6 months eGFR - POD-1 eGFR; Δ3 = 12 months eGFR - 6 months eGFR. We defined POD-1 acute kidney injury (AKI) as an increase in serum creatinine by ≥ 0.3 mg/dl or a 1.5 1.9-fold from baseline. Additionally, a cutoff of 60 ml/min in eGFR was considered to define renal function decline at 6 and 12 months. Logistic regression (LR) and linear mixed (LM) models were used to evaluate the association between clinical factors and eGFR decline and their interaction with follow-up.

RESULTS:

A total of 576 were included, of these 409(71.0%) and 403(70.0%) had an eGFR < 60 ml/min at 6 and 12 months, respectively, and 239(41.5%) developed POD-1 AKI. In multivariable LR analysis, age (Odds Ratio, OR 1.05, p < 0.001), male gender (OR 0.44, p = 0.003), POD-1 AKI (OR 2.88, p < 0.001) and preoperative eGFR < 60 ml/min (OR 7.58, p < 0.001) were predictors of renal function decline at 6 months. Age (OR 1.06, p < 0.001), coronary artery disease (OR 2.68, p = 0.007), POD-1 AKI (OR 1.83, p = 0.02), and preoperative eGFR < 60 ml/min (OR 7.80, p < 0.001) were predictors of renal function decline at 12 months. In LM models, age (p = 0.019), hydronephrosis (p < 0.001), POD-1 AKI (p < 0.001) and pT-stage (p = 0.001) influenced renal function variation (ß 9.2 ± 0.7, p < 0.001) during follow-up.

CONCLUSION:

Age, preoperative eGFR and POD-1 AKI are independent predictors of 6 and 12 months renal function decline after RNU for UTUC.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ureterales / Sistema Urinario / Neoplasias de la Vejiga Urinaria / Carcinoma de Células Transicionales / Neoplasias Urológicas / Lesión Renal Aguda Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Infant / Male Idioma: En Revista: World J Urol Año: 2022 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ureterales / Sistema Urinario / Neoplasias de la Vejiga Urinaria / Carcinoma de Células Transicionales / Neoplasias Urológicas / Lesión Renal Aguda Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Infant / Male Idioma: En Revista: World J Urol Año: 2022 Tipo del documento: Article País de afiliación: Italia
...